Conditions: Hepatic Impairment
Keywords: hepatic impairment
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 32
Healthy volunteers: yes

Brief summary:
This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched healthy subjects

Detailed description:

Arms:
arm 1: LCZ696 200 mg, given as a single oral dose arm 2: LCZ696 200 mg, given as a single oral dose arm 3: LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2

Interventions: intervention 1: LCZ696
Intervention descriptions: intervention 1: None

Protocol document: